Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says

Bioventus (NYSE:BVS) had its target price upped by analysts at Barrington Research from $13.00 to $14.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Barrington Research’s price objective points to a potential upside of 65.09% from the company’s current price.

Separately, Craig Hallum upped their price target on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $14.25.

Bioventus Price Performance

NYSE:BVS traded down $0.62 during mid-day trading on Friday, reaching $8.48. The stock had a trading volume of 209,449 shares, compared to its average volume of 273,323. Bioventus has a one year low of $5.81 and a one year high of $11.25. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a 50 day moving average price of $8.10 and a two-hundred day moving average price of $7.49. The stock has a market capitalization of $701.83 million, a P/E ratio of -13.90 and a beta of 0.78.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its position in Bioventus by 17,156.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares during the last quarter. Anderson Financial Strategies LLC grew its position in shares of Bioventus by 58.3% during the fourth quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock worth $1,586,000 after acquiring an additional 78,488 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Bioventus by 52.9% during the fourth quarter. Invesco Ltd. now owns 33,621 shares of the company’s stock worth $250,000 after buying an additional 11,639 shares during the period. Corient Private Wealth LLC increased its position in Bioventus by 44.9% in the 4th quarter. Corient Private Wealth LLC now owns 19,471 shares of the company’s stock valued at $145,000 after acquiring an additional 6,031 shares during the period. Finally, Mercer Global Advisors Inc. ADV raised its stake in Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after acquiring an additional 1,887 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus News Roundup

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Strong Q4 results: Q4 revenue of $157.9M (+2.8% y/y) with organic revenue +10%, GAAP EPS $0.21, non‑GAAP EPS $0.24, and cash from operations of $38.0M (up 97%). This quarter provides near‑term proof of improving profitability and cash generation. Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY‑2026 guidance and targets: management outlined a $600M–$610M 2026 sales target and issued EPS guidance of $0.73–$0.77, slightly above consensus — signaling confidence in growth drivers (PNS, PRP, ultrasonics) and margin expansion. Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and
• Positive Sentiment: Analyst upgrade: Craig Hallum raised its price target to $16 and maintains a “buy” rating, implying material upside from current levels and adding buy‑side validation. Benzinga
• Neutral Sentiment: Investor materials available: full earnings call transcript and presentation published (useful for digging into product‑level trends and 2026 investment priorities). Bioventus (BVS) Q4 2025 Earnings Call Transcript Bioventus Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Short‑term pullback/volatility: shares had jumped after the earnings beat, and today’s decline likely reflects profit‑taking and short‑term rotation rather than a change to the company’s fundamentals.
• Negative Sentiment: Balance‑sheet and valuation considerations: investors may be weighing a modest liquidity profile (quick ratio ~0.99), relatively high leverage (debt‑to‑equity ~1.85) and mixed multi‑quarter profitability metrics when setting near‑term expectations.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.